112 related articles for article (PubMed ID: 27726885)
1. [Cyamemazine (Tercian
Khouri C; Lepelley M; Villier C; Bougerol T; Mallaret M;
Therapie; 2017 Jun; 72(3):345-350. PubMed ID: 27726885
[TBL] [Abstract][Full Text] [Related]
2. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).
Hodé Y; Reimold M; Demazières A; Reischl G; Bayle F; Nuss P; Hameg A; Dib M; Macher JP
Psychopharmacology (Berl); 2005 Jul; 180(2):377-84. PubMed ID: 15948013
[TBL] [Abstract][Full Text] [Related]
3. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects.
Keepers GA; Casey DE
Am J Psychiatry; 1991 Jan; 148(1):85-9. PubMed ID: 1670616
[TBL] [Abstract][Full Text] [Related]
4. [Neuroleptic associated hypothermia: a new case report and study of spontaneous reports to the French pharmacovigilance network].
Huguet B; Fongue J; Chiche L; Gilly L; Pastor MJ; Michelet P; Rouby F
Rev Med Interne; 2015 Feb; 36(2):124-6. PubMed ID: 24156974
[TBL] [Abstract][Full Text] [Related]
5. Incidence of extrapyramidal syndromes in AIDS patients and a comparison group of medically ill inpatients.
Ramachandran G; Glickman L; Levenson J; Rao C
J Neuropsychiatry Clin Neurosci; 1997; 9(4):579-83. PubMed ID: 9447500
[TBL] [Abstract][Full Text] [Related]
6. Painful sensory symptoms in neuroleptic-induced extrapyramidal syndromes.
Decina P; Mukherjee S; Caracci G; Harrison K
Am J Psychiatry; 1992 Aug; 149(8):1075-80. PubMed ID: 1353315
[TBL] [Abstract][Full Text] [Related]
7. Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine.
Peinado J; Hameg A; Garay RP; Bayle F; Nuss P; Dib M
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):134-9. PubMed ID: 12595954
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database.
Peyrière H; Roux C; Ferard C; Deleau N; Kreft-Jais C; Hillaire-Buys D; Boulenger JP; Blayac JP;
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):948-55. PubMed ID: 19572384
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic drug monitoring of cyamemazine: How to interpret a concentration? A review of literature].
Alarcan H; Schnell D; Rouleau S; Chachia A; Saint-Marcoux F; Mathieu O; Couderc S
Therapie; 2022; 77(5):603-609. PubMed ID: 35221129
[TBL] [Abstract][Full Text] [Related]
10. Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database.
Perez-Lloret S; Rey MV; Bondon-Guitton E; Rascol O; Montastruc AJ;
J Clin Psychopharmacol; 2012 Dec; 32(6):824-7. PubMed ID: 23131889
[TBL] [Abstract][Full Text] [Related]
11. Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes.
Dose M
Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():3-13. PubMed ID: 11072761
[TBL] [Abstract][Full Text] [Related]
12. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
13. [Acute-onset extrapyramidal syndromes caused by drugs].
Montoya Cabrera MA; López Martín G; Baca Rodríguez LC; Porcayo Vergara F; Hernández Zamora A; Juárez Aragón G
Bol Med Hosp Infant Mex; 1981; 38(4):607-15. PubMed ID: 6117295
[TBL] [Abstract][Full Text] [Related]
14. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
Modestin J; Wehrli MV; Stephan PL; Agarwalla P
Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
[TBL] [Abstract][Full Text] [Related]
15. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
Casey DE
Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
[TBL] [Abstract][Full Text] [Related]
16. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
[TBL] [Abstract][Full Text] [Related]
17. Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome.
Favre JD; Allain H; Aubin HJ; Frija-Orvoen E; Gillet C; Lejoyeux M; Payen A; Weber M; Garcia-Acosta S; Kermadi I; Dib M
Hum Psychopharmacol; 2005 Oct; 20(7):511-9. PubMed ID: 16118830
[TBL] [Abstract][Full Text] [Related]
18. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
[TBL] [Abstract][Full Text] [Related]
19. [Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases].
Masmoudi K; Gras-Champel V; Lemaire-Hurtel AS; Masson H; Munier A; Geslin JM; Andréjak M
Rev Med Interne; 2005 Jun; 26(6):453-7. PubMed ID: 15936474
[TBL] [Abstract][Full Text] [Related]
20. [Drugs and retinal disorders: A case/non-case study in the French pharmacovigilance database].
Bourgeois N; Chavant F; Lafay-Chebassier C; Leveziel N; Pérault-Pochat MC
Therapie; 2016 Sep; 71(4):365-74. PubMed ID: 27203167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
